



Thursday, 24 May 2018

13.00-13.30		Opening of the EUFEPS 2018	
13.30-14.00		<p align="center">Plenary Lecture 1 <i>Stefan Knapp, Goethe University, Germany, "Novel Molecular Targets"</i></p>	
14.00-14.30		<p align="center">Plenary Lecture 2 <i>Mansoor Khan, Texas A&M University Rangel College of Pharmacy, "Innovations and Nanomedicines: Balancing Responsible Science with Regulations for Success"</i></p>	
14.30-15.00		<p align="center">Plenary Lecture 3 <i>Jukka Rantanen, University of Copenhagen, Denmark, "Manufacturing of Personalized Medicines"</i></p>	
15.00-15.30		Coffee break	
Parallel sessions I			
15.30-17.00	Physiology of the GI tract relevant for drug absorption	Nanomedicines and nanosimilars: How to assess how similar? <i>Organized by EUFEPS Nanomedicine Network</i>	
15.30-16.00	<i>Patrick Augustijns, "What do we know and what should we understand better? "</i>	<i>Gerrit Borchard, "Bench to Mensch and back: Identifying critical quality attributes for nanomedicines"</i>	
16.00-16.30	<i>Martin Brandl, "Colloidal structures and drug absorption: from amorphous nanoparticles to bile salt micelles"</i>	<i>Beatriz Silva Lima, "Regulator's point of view for nanomedicines and nanosimilars"</i>	
16.30-17.00	<i>Panos Macheras, "Do we need to consider a reaction limited in Vivo drug dissolution model?"</i>	Selections from abstracts – Oral presentations	
17.00-18.00	Flash oral presentations session (5 min each) EUFEPS Networks presentations		
19.00-21.00	Opening ceremony and welcome reception at University Rectorate Building under the patronage of Rector University of Athens		



Friday, 25 May 2017

09.00- 09.30	Plenary Lecture 4	
	<i>Leslie Benet, University of California San Francisco, USA “Calculating extraction ratios and predicting IVIVE: The unrecognized assumptions”</i>	
09.30-10.00	Plenary Lecture 5	
	The Douwe Breimer Lecture, Per Artursson, Uppsala University, Sweden	
10.00-10.30	Coffee break	
Parallel sessions II		
	Performance of dosage forms in the body and impact on drug absorption	Nanomedicines: Challenges on the road <i>Organized by EUFEPS Nanomedicine Network</i>
10.30-11.00	Werner Weitschies, “GI physiology vs. formulation technology: who is in the driving seat?”	Richard Harvey, “Antimicrobial nanomedicines for pulmonary delivery”
11.00-11.30	Vaggelis Karalis, “Pharmacokinetic modeling in Research/Development of drugs.”	Maria Blanco Prieto, “Cardiac Drug Delivery with nanoparticulate delivery systems”
11.30-12.00	Selections from abstracts – Oral presentations	Selections from abstracts – Oral presentations
12.00-13.30	Lunch break	
Parallel sessions III		
	Drug absorption, dissolution and in-silico modelling – towards prediction paradise?	Manufacturing of future medicines <i>(Co-organized with Glatt)</i>
13.30-14.00	M. Vertzoni, “Advances in biorelevant oral drug product performance testing”	Karl-Heinz Seyfang, lecture title to be announced
14.00-14.30	Christos Reppas, “Drug absorption from the lower intestine? “	TBD
14.30-15.00	Selections from abstracts – Oral presentations	Selections from abstracts – Oral presentations



15.00-15.30	Coffee break	
Parallel sessions IV		
	Information on drug absorption in regulatory processes: nice-to-know vs. need-to-know EUFEPS Network Bioavailability and Biopharmaceutics (BABP)	Nanomedicines: The European Platform and Status <i>Organized by EUFEPS Nanomedicine Network</i>
15.30 -16.00	Tomas Salmonson , "What do regulators expect in case on new drugs?"	Adriele Prina-Mello , "EU-NCL Towards a European Nanotechnology Characterization Lab"
16.00-16.30	Jan Welink , "Drug absorption and BE assessment: who cares? "	Caroline Lemarchand , "Nanomedicine spin-off company experience"
16.30-17.00	Annette Bauer-Brandl , "Vitro performance Ranking of bioavailability-enhancing oral formulations: Recent advances"	Rana Sanyal , "From Synthesis toward Clinical: An experience in Nanomedicine"
Parallel sessions V		
	Oral drug absorption: Science & Regulation EUFEPS Network Pharmacogenetics Research and Implementation (EPRIN)	Biotech and Biosimilars: What is the next step for the future
17.00-17.30	Magnus-Ingelman Sundberg , "Personalized medicine: Challenges of rare genetic variants in prediction of drug response and adverse drug reactions"	Umay Şaplakoğlu , "Continuous manufacturing of biotech drugs"
17.30-18.00	Andrew Owen , "Towards stratified medicine approaches using nanotechnology-based drug delivery systems: A focus on infectious diseases"	Ulrike Konrad , "Biosimilar development from scratch to clinics"
18.00-18.30	Selected from abstracts	Arnold Vulto , "Clinical evaluation and interchangeability of biotech products from clinical pharmacist's point of view"
19.30	Conference Dinner at Aegli	



Saturday, 26 May 2017			
09.00 - 09.30	<p align="center">Plenary Lecture 5 <i>Sir Munir Pirmohamed, University of Liverpool, "Personalized medicine in order to optimize drug efficacy and minimize toxicity"</i></p>		
09.30-10.00	<p align="center">Plenary Lecture 6 <i>Ivana Knezevic, WHO Group Lead for Norms and Standards for Biological Technologies, Switzerland "Biotech Drugs and Biosimilars: Global Perspective and Clinical Acceptance"</i></p>		
10.00-10.30	<p align="center">Coffee break</p>		
Parallel sessions VI			
	EUFEPS Network Systems Pharmacology	Biotech and Biosimilars	Nanotechnology in Health Sciences HSNanoHS Workshop
10.30 -11.00	Robert Bies , "On the dilemma of irreproducibility: Inherent or statistical"	Despoina Sanoudou , "Genomics and Molecular Biology in drug development and assessment"	Imaging and diagnostics
11.00 -11.30	Aris Dokoumetzidis , "Extrapolation of drug's efficacy from adults to children using pharmacokinetic/pharmacodynamic modelling"	irem Yenice , "Development of a biosimilar monoclonal antibody drug"	
11.30-12.00	Lars Kuepfer , lecture title to be announced	TBC	Drug delivery and therapeutics
12.00-13.30	<p align="center">Lunch break</p>		
Parallel sessions VII			
	Regulatory Science: Partnerships looking into the future <i>EUFEPS Network on Regulatory Science</i>	New drugs in Oncology <i>German Pharmaceutical Society DPhG</i>	Drug delivery and therapeutics



EUFEPS Annual Meeting 2018

Crossing Barriers for Future Medicines



24-26/05/2018

Titania Hotel
Athens, Greece



13.30-14.00	Beatriz Silva Lima , TBA	Stefan Laufer , "EGFR Triple Mutant: Recent Set-Backs and New Hopes in Fighting Mutant Non-Small Cell Lung Cancer"	Theranostics
14.00-14.30	Bert Leufkens , TBA	Kristian Strømgaard , "Targeting syntenin and inhibition of cancer"	
14.30-15.00	Rogério Gaspar , TBA	Romano Silvestri , "New anti-cancer agents through an interaction with tubulin"	
14.30-15.00	Awards and Closing ceremony		